AbbVie Inc.
ABBV
#28
Rank
$464.575 B
Marketcap
United States
Country
$262.90
Share price
5.12%
Change (1 day)
18.25%
Change (1 year)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly…
Key Metrics
Trailing P/E
74.58
Forward P/E
16.23
EPS (TTM)
$3.54
Forward EPS
$16.27
Price / Book
—
EV / EBITDA
17.2x
Beta
0.28
Dividend Yield
2.64%
Return on Equity
—
Return on Assets
10.51%
Debt / Equity
—
Current Ratio
0.81
Gross Margin
72.79%
Operating Margin
40.03%
Net Profit Margin
9.80%
Free Cash Flow
$16.870B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 18 – Sep 17
+1.97%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$61.160B
Latest Net Income$4.226B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare AbbVie Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ABBV
No recent news available. Set FINNHUB_API_KEY to enable news.
